Citations

Showing 10 of 108083 citations.

Endoscopic Ultrasound-guided Transluminal Gallbladder Drainage in Patients With Acute Cholecystitis
Irani, Shayan , Sharma, Neil , Chahal, Prabhleen , Baron, Todd H. , Kozarek, Richard A. , Peetermans, Joyce , McMullen, Edmund, Ho, Evelyne, Merwe, Van der , Storm, Andrew C. , Shah, Raj J. , Willingham, Field F. , Swanström, Lee L. , Shlomovitz, Eran

Mayo Clinic

Annals of Surgery | December 20, 2022 | Volume: 278 | Issue: 3 | Pages: e556-e562

10.1097/sla.0000000000005784 | PMID 36537290 Get It

Objective: To evaluate the safety and efficacy of endoscopic ultrasound-guided gallbladder drainage (EUS-GBD) using a lumen-apposing metal stent (LAMS). Background: For patients with acute cholecystitis who are poor surgical candidates, EUS-GBD using a LAMS is an important treatment alternative to percutaneous gallbladder drainage. Methods: We conducted a regulatory-compliant, prospective multicenter trial at 7 tertiary referral centers in the United States of America and Belgium. Thirty consecutive patients with mild or moderate acute cholecystitis who were not candidates for cholecystectomy were enrolled between September 2019 and August 2021. Eligible patients had a LAMS placed transmurally with 30 to 60-day indwell if removal was clinically indicated, and 30-day follow-up post-LAMS removal. Endpoints included days until acute cholecystitis resolution, reintervention rate, acute cholecystitis recurrence rate, and procedure-related adverse events (AEs). Results: Technical success was 93.3% (28/30) for LAMS placement and 100% for LAMS removal in 19 patients for whom removal was attempted. Five (16.7%) patients required reintervention. Mean time to acute cholecystitis resolution was 1.6±1.5 days. Acute cholecystitis symptoms recurred in 10.0% (3/30) after LAMS removal. Five (16.7%) patients died from unrelated causes. Procedure-related AEs were reported to the FDA in 30.0% (9/30) of patients, including one fatal event 21 days after LAMS removal; however, no AEs were causally related to the LAMS. Conclusions: For selected patients with acute cholecystitis who are at elevated surgical risk, EUS-GBD with LAMS is an alternative to percutaneous gallbladder drainage. It has high technical and clinical success, with low recurrence and an acceptable AE rate. Clinicaltrials.gov, Number: NCT03767881.
Prevalence of mental health symptoms in children and adolescents during the COVID‐19 pandemic: A meta‐analysis
Deng, Jiawen , Zhou, Fangwen , Hou, Wenteng , Heybati, Kiyan , Lohit, Simran , Abbas, Umaima , Silver, Zachary , Wong, Chi Yi , Chang, Oswin , Huang, Emma , Zuo, Qi , Moskalyk, Myron , Ramaraju, Harikrishnaa Ba , Heybati, Shayan , Deng, J , Zhou, F

Mayo Clinic

Annals of the New York Academy of Sciences | December 20, 2022 | Volume: 1520 | Issue: 1 | Pages: 53-73

10.1111/nyas.14947 | PMID 36537131 Get It

Abstract The COVID‐19 pandemic and its accompanying infection control measures introduced sudden and significant disruptions to the lives of children and adolescents around the world. Given the potential for negative impacts on the mental health of youths as a result of these changes, we conducted a systematic review and meta‐analysis to examine the prevalence of depressive symptoms, anxiety symptoms, and sleep disturbances in children and adolescents during the pandemic. We searched major literature databases for relevant cross‐sectional or longitudinal studies that included primary and secondary school students or children and adolescents ≤18 years of age. Prevalence values were extracted, logit‐transformed, and pooled. Based on 191 included studies with 1,389,447 children and adolescents, we found the pooled prevalence of depressive symptoms, anxiety symptoms, and sleep disturbances to be 31%, 31%, and 42%, respectively. Age, grade levels, education levels, gender, geographical regions, and electronics use were correlated with the prevalence of mental health symptoms. The prevalence of mental health symptoms also increased with time, although signs of recovery and stabilization were also observed. Overall, the results from this review demonstrate the need for increased mental health research, monitoring, and intervention for children and adolescents during the current and future pandemics.
An Analysis of Malpractice Litigation of Vascular Surgeons in Cases Involving Aortic Pathologies
Sen, Indrani , Choudhry, Asad , Cherukuri, Sai Kiran, Mendes, Bernardo C. , Colglazier, Jill J. , Shuja, Fahad , Kalra, Manju , DeMartino, Randall R. , Rasmussen, Todd E.

Mayo Clinic

Vascular and Endovascular Surgery | December 20, 2022 | Volume: 57 | Issue: 4 | Pages: 350-356

10.1177/15385744221146389 | PMID 36537051 Get It

Objective The aim of this study was to analyze malpractice claims for aortic pathologies and to assess if there has been a change in rate of malpractice lawsuits with evolution of endovascular therapy. Methods Malpractice lawsuits were individually screened and compiled from the Westlaw database from 2000 to 2017 through use of relevant search terms. Data were collected of allegations, diagnoses, and outcomes of each case and compared. Results 268 unique cases were included in this study, with aneurysms (54%, n = 145) and dissection (35%, n = 94) making up the majority. There was a defendant verdict in 53% (n = 141), plaintiff verdict in 24% (n = 65), and settlements in 23% (n = 62) of lawsuits. Litigation was higher in the Midwest and Northeast. There was a gradual decline in litigation overall, however endovascular case numbers remained constant. There was negligible difference in the primary allegation underlying the litigation for various aortic pathologies, time to litigation and award between open and endovascular procedures. Conclusion The proportion of litigation for clinical negligence in endovascular cases amongst all vascular surgical lawsuits is increasing. As novel methods of endovascular therapy emerge, it is imperative that physicians remain vigilant to legal considerations to minimize malpractice risk.
Cleft Palate Repair Postoperative Management: Current Practices in the United States
Sitzman, Thomas J. , Verhey, Erik M., Kirschner, Richard E. , Pollard, Sarah Hatch , Baylis, Adriane L. , Chapman, Kathy , Sitzman, Thomas J , Chapman, Kathy L.

Mayo Clinic

The Cleft Palate Craniofacial Journal | December 20, 2022 | Volume: 61 | Issue: 5 | Pages: 827-833

10.1177/10556656221146891 | PMID 36536584 Get It

Objective To describe current postoperative management practices following cleft palate repair. Design A survey was administered to cleft surgeons to collect information on their demographic characteristics, surgical training, surgical practice, and postoperative management preferences. Setting Eighteen tertiary referral hospitals across the United States. Participants: Surgeons (n = 67) performing primary cleft palate repair. Results Postoperative diet restrictions were imposed by 92% of surgeons; pureed foods were allowed at one week after surgery by 90% of surgeons; a regular diet was allowed at one month by 80% of surgeons. Elbow immobilizers and/or mittens were used by 85% of surgeons, for a median duration of two weeks. There was significant disagreement about postoperative use of bottles (61% allow), sippy cups (68% allow), pacifiers (29% allow), and antibiotics (45% prescribe). Surgeon specialty was not associated with any aspect of postoperative management ( p > 0.05 for all comparisons). Surgeon years in practice, a measure of surgeon experience, was associated only with sippy cup use ( p < 0.01). The hospital at which the surgeon practiced was associated with diet restrictions ( p < 0.01), bottle use ( p < 0.01), and use of elbow immobilizers or mittens ( p < 0.01); however, many hospitals still had disagreement among their surgeons. Conclusions Surgeons broadly agree on diet restrictions and the use of elbow immobilizers or mittens following palate repair. Almost all other aspects of postoperative management, including the type and duration of diet restriction as well as the duration of immobilizer use, are highly individualized.
Sinonasal Outcomes Using Oral Corticosteroids in Patients with Chronic Rhinosinusitis with Nasal Polyps and Positive Sinonasal Cultures
Martinez‐Paredes, Jhon F. , Donaldson, Angela M. , Marino, Michael J. , Olomu, Osarenoma , Alfakir, Razan , Stokken, Janalee K., O’Brien, Erin K. , Lal, Devyani , Marino, Michael J , Choby, Garret , Olomu, Osarenoma , Alfakir, Razan , O'Brien, Erin K , Lal, Devyani , Choby, Garret

Mayo Clinic

International Archives of Otorhinolaryngology | December 20, 2022 | Volume: 27 | Issue: 02 | Pages: e286-e295

10.1055/s-0042-1743275 | PMID 37125375 Get It

Abstract Introduction Patients with chronic rhinosinusitis with nasal polyps (CRSwNP) and positive sinonasal bacterial cultures may be recalcitrant to topical therapy alone due to the additional local inflammatory burden associated with bacterial infection/colonization. Objective To evaluate sinonasal outcomes in CRSwNP patients with a positive perioperative bacterial culture, who were treated with postoperative intranasal corticosteroids (INCS) alone versus INCS in combination with a short-term course of oral corticosteroids (OCS). Methods This is a retrospective chart review of CRSwNP patients. A total of 59 patients met inclusion criteria, including positive perioperative bacterial culture and treatment with INCS with or without concomitant use of OCS. Two cohorts were formed based on the chosen postoperative medical treatment; 32 patients underwent postoperative INCS alone, while 27 underwent INCS plus a ≤ 2-week course of OCS. The 22-item sinonasal outcome test (SNOT-22) scores and Lund-Kennedy scores (LKS) were assessed preoperatively, and at 2-week, 4-week, and 4 to 6 months after endoscopic sinus surgery (ESS). Results There were no statistically significant differences in postoperative sinonasal symptoms or endoscopic scores between the cohorts treated with INCS plus OCS versus those prescribed INCS alone (p > 0.05). Our regression model failed to demonstrate a relationship between the use of OCS and better sinonasal outcomes at 2-week, 4-week, and 4 to 6 months after ESS (p > 0.05). Conclusion Our study suggests that in a cohort of CRSwNP patients with recent bacterial infections, the postoperative use of combined OCS and INCS did not result in a statistical improvement of endoscopic and symptomatic outcomes over INCS irrigation alone. However, both treatment groups had a clinically significant improvement based on the Minimal Clinically Important Difference.
Daratumumab, Carfilzomib, Pomalidomide and Elotuzumab for the Treatment of POEMS Syndrome- The Mayo Clinic Experience
Kumar, Shaji , Buadi, Francis K. , Lacy, Martha Q. , Dingli, David , Hayman, Suzanne R. , Kourelis, Taxiarchis , Warsame, Rahma , Hwa, Yi L. , Fonder, Amie , Hobbs, Miriam, Kapoor, Prashant , Lin, Yi, Siddiqui, Mustaqeem , Kyle, Robert A. , Buadi, Francis K , Siddiqui, Mustaqeem A , Dingli, David , Vaxman, Iuliana , Muchtar, Eli , Leung, Nelson , Go, Ronald S. , Gonsalves, Wilson I. , Rajkumar, S. Vincent , Gertz, Morie A. , Dispenzieri, Angela

Mayo Clinic

No container title available | December 19, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-2325390/v1 Get It

Abstract POEMS syndrome is a rare paraneoplastic syndrome and therapies are directed against plasma cells that produce the proteins that cause this syndrome. Novel therapies are widely used in multiple myeloma aiming for plasma cell eradication. However, data on their use in POEMS syndrome are lacking. In this case series, we provide the Mayo Clinic experience in treating 16 patients with relapsed POEMS syndrome with novel agents (daratumumab, carfilzomib, pomalidomide, and elotuzumab). The patients were treated with a doublet including dexamethasone (N = 5) (31%) or in various combinations with other agents: DRd (N = 6), DC(V)d (N = 3), KRd (N = 3), KPd (N = 1), DP(V)d (N = 5), and EloRd (N = 1). The outcomes with novel agent therapies were favorable. Overall, twelve patients treated with daratumumab-based therapies (86%) and five patients treated with carfilzomib-based therapies (83%) responded to therapy. Among patients treated with daratumumab based therapies (N = 14), 9 patients achieved CR/VGPRH, 7 patients achieved CRV, and 5 patients achieved CRP. Among patients treated with carfilzomib-based therapies (N = 6), 3 patients achieved CR/VGPRH, and one achieved PRH. At a median follow-up of 38 months since starting of the novel agent (IQR 24–57), 15 of the patients (93%) are still alive, and the median TTNT was not reached. None of the patients discontinued therapy due to adverse events and no deaths occurred on therapy. Novel therapies were safe with 7 events of hospitalization due to pneumonia (4 in daratumumab-based therapies and 3 on carfilzomib-based therapies), and 4 patients were hospitalized due to volume overload. Three patients experienced infusion-related reactions (IRR) to the first dose of IV daratumumab. The response rate to novel agents was high, and the responses were deep. Novel agent therapies were safe, and no death case occurred on therapy. Future studies are needed to clarify the optimal sequence of novel agents and the best combination.
Annals Consult Guys - Postoperative Atrial Fibrillation
Weitz, Howard H. , Merli, Geno J. , Siontis, Konstantinos C.

Mayo Clinic

Annals of Internal Medicine | December 19, 2022 | Volume: 175 | Issue: 12 | Pages: CG1

10.7326/w21-0013 | PMID 36534998 Get It

Annals On Call - Benefits of Sigmoidoscopy for Colon Cancer Screening
Centor, Robert M. , West, Colin P.

Mayo Clinic

Annals of Internal Medicine | December 19, 2022 | Volume: 175 | Issue: 12 | Pages: OC1

10.7326/a21-0025 | PMID 36534997 Get It

White-matter abnormalities in presymptomaticGRNandC9orf72mutation carriers
Lee, Hyunwoo , Mackenzie, Ian R. , Popuri, Karteek , Rademakers, Rosa , Wittenberg, Dana, Beg, Mirza Faisal , Hsiung, Ging‐Yuek Robin

Mayo Clinic

Brain Communications | December 19, 2022 | Volume: 5 | Issue: 1 | Pages: No page available

10.1093/braincomms/fcac333 | PMID 36632182 Get It

AbstractA large proportion of familial frontotemporal dementia is caused by TAR DNA-binding protein 43 (transactive response DNA-binding protein 43 kDa) proteinopathies. Accordingly, carriers of autosomal dominant mutations in the genes associated with TAR DNA-binding protein 43 aggregation, such as Chromosome 9 open reading frame 72 (C9orf72) or progranulin (GRN), are at risk of later developing frontotemporal dementia. Brain imaging abnormalities that develop before dementia onset in mutation carriers may serve as proxies for the presymptomatic stages of familial frontotemporal dementia due to a genetic cause. Our study objective was to investigate brain MRI-based white-matter changes in predementia participants carrying mutations in C9orf72 or GRN genes. We analysed mutation carriers and their family member controls (noncarriers) from the University of British Columbia familial frontotemporal dementia study. First, a total of 42 participants (8 GRN carriers; 11 C9orf72 carriers; 23 noncarriers) had longitudinal T1-weighted MRI over ∼2 years. White-matter signal hypointensities were segmented and volumes were calculated for each participant. General linear models were applied to compare the baseline burden and the annualized rate of accumulation of signal abnormalities among mutation carriers and noncarriers. Second, a total of 60 participants (9 GRN carriers; 17 C9orf72 carriers; 34 noncarriers) had cross-sectional diffusion tensor MRI available. For each participant, we calculated the average fractional anisotropy and mean, radial and axial diffusivity parameter values within the normal-appearing white-matter tissues. General linear models were applied to compare whether mutation carriers and noncarriers had different trends in diffusion tensor imaging parameter values as they neared the expected age of onset. Baseline volumes of white-matter signal abnormalities were not significantly different among mutation carriers and noncarriers. Longitudinally, GRN carriers had significantly higher annualized rates of accumulation (estimated mean: 15.87%/year) compared with C9orf72 carriers (3.69%/year) or noncarriers (2.64%/year). A significant relationship between diffusion tensor imaging parameter values and increasing expected age of onset was found in the periventricular normal-appearing white-matter region. Specifically, GRN carriers had a tendency of a faster increase of mean and radial diffusivity values and C9orf72 carriers had a tendency of a faster decline of fractional anisotropy values as they reached closer to the expected age of dementia onset. These findings suggest that white-matter changes may represent early markers of familial frontotemporal dementia due to genetic causes. However, GRN and C9orf72 mutation carriers may have different mechanisms leading to tissue abnormalities.